Slingshot members are tracking this event:

Global Blood Therapeutics Announces Presentation of New GBT440 Data in Sickle Cell Disease at the European Hematology Association's 21st Congress

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
GBT Community voting in process

Additional Information

Additional Relevant Details The presentations will include additional data from the ongoing Phase 1/2 GBT440-001 study in sickle cell disease (SCD), including 90-day data from a cohort of patients taking 700 mg of GBT440, 28-day results from three dosing cohorts of GBT440 and additional data on the pharmacokinetics and pharmacodynamics of GBT440.
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 19, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Gbt440, Sickle Cell Disease, Gbt440-001, Oxygenated Sickle Hemoglobin, Polymerize, Red Blood Cells